Table 3.
Risk assessment models |
Guidelines for care of metastatic PPGL |
Surveillance programs for mutation carriers |
Access to treatment opportunities |
Genetic testing: not widely available |
Opportunities for communication and discussion of care/surveillance of specific cases |